Organogenesis Expects 5% To 11% Revenue Growth In 2024

Shares of Organogenesis Holdings Inc. (ORGO) are down 29% from their 52-week of $4.57, recorded last November, and trade around $3.

This regenerative medicine company is focused on the development and sale of products for the advanced wound care, and surgical and sports medicine markets.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com